Compare SRPT & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | VET |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2000 | 2004 |
| Metric | SRPT | VET |
|---|---|---|
| Price | $15.89 | $11.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 29 | 1 |
| Target Price | ★ $25.85 | $15.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | $14.07 |
| Revenue Next Year | N/A | $3.40 |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $7.00 |
| 52 Week High | $43.92 | $14.82 |
| Indicator | SRPT | VET |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 40.68 |
| Support Level | $15.70 | $11.14 |
| Resistance Level | $19.62 | $12.00 |
| Average True Range (ATR) | 0.73 | 0.43 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 1.96 | 16.13 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.